Major Ingredients

Each film coated tablet contains Afatinib 40 mg as Afatinib Dimaleate INN.

Major Functionality

EGFR Mutation-Positive, Metastatic Non-Small Cell Lung Cancer: Anib is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. Limitation of Use: The safety and efficacy of Anib have not been established in patients whose tumors have other EGFR mutations. Previously Treated, Metastatic Squamous NSCLC: Anib is indicated for the treatment of patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy.

Manufacture Information

Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.